Healthcare
•3755 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (3755)
| Company | Market Cap | Price |
|---|---|---|
|
ARAY
Accuray Incorporated
Accuray's CyberKnife and TomoTherapy/Radixact systems rely on advanced medical imaging for planning and guidance.
|
$99.63M |
$0.88
-0.60%
|
|
ULBI
Ultralife Corporation
Products targeted at medical use (X5 medical care products, wearable power) place Ultralife in Medical Devices & Biometrics.
|
$97.86M |
$6.11
-1.13%
|
|
XTNT
Xtant Medical Holdings, Inc.
Company designs, manufactures, and sells orthopedic surgical implants (e.g., spinal implants) and orthobiologic products.
|
$97.35M |
$0.73
-6.45%
|
|
NCSM
NCS Multistage Holdings, Inc.
Tracer diagnostics capabilities and studies are a key service offering for reservoir and well performance analysis.
|
$95.97M |
$37.16
-2.70%
|
|
CSBR
Champions Oncology, Inc.
Company provides outsourced drug development and preclinical/clinical research services to biopharma (CRO-style).
|
$93.49M |
$6.76
-0.46%
|
|
HIT
Health In Tech, Inc.
HIT operates in health insurance by enabling quotes, plans, and related services through its platform.
|
$93.04M |
$1.65
+2.81%
|
|
CBUS
Cibus, Inc.
Reported contract research revenue indicates direct R&D services provided to clients alongside platform licensing.
|
$91.66M |
$1.68
+5.66%
|
|
ADVM
Adverum Biotechnologies, Inc.
Lead program Ixo-vec is a gene therapy for an ocular indication, placing Adverum in the Biotech - Gene Therapy category.
|
$91.49M |
$4.38
+0.34%
|
|
RCEL
AVITA Medical, Inc.
RECELL System and Cohealyx/PermeaDerm are wound care devices used for wound closure and healing.
|
$90.50M |
$3.33
+1.52%
|
|
COYA
Coya Therapeutics, Inc.
COYA's autologous regulatory T cell therapy program (COYA 101) represents a direct cell therapy product line.
|
$89.65M |
$5.36
-0.09%
|
|
KRRO
Korro Bio, Inc.
KRRO's core offering is its OPERA oligonucleotide platform enabling RNA editing therapeutics (oligonucleotide-based editing).
|
$89.21M |
$9.56
+4.48%
|
|
SCLX
Scilex Holding Company
Core business focused on non-opioid pain management drugs and a pipeline of non-opioid therapies.
|
$89.03M |
$13.40
+0.87%
|
|
CALC
CalciMedica, Inc.
CalciMedica's lead candidate Auxora is a CRAC channel inhibitor, i.e., an ion channel modulator.
|
$88.72M |
$5.77
+17.76%
|
|
ONCY
Oncolytics Biotech Inc.
Pelareorep is an oncolytic virus immunotherapy developed by Oncolytics Biotech, placing the company in Biotech - Oncology.
|
$88.06M |
$0.97
-2.28%
|
|
DCGO
DocGo Inc.
DocGo directly provides Home Health & Hospice services, including in-home/mobile healthcare delivery.
|
$87.45M |
$0.90
-0.99%
|
|
BHST
BioHarvest Sciences Inc. Common Stock
BioHarvest operates a CDMO division providing contract development and manufacturing services for plant-based compounds.
|
$86.84M |
$5.04
-1.27%
|
|
KBLB
Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories produces recombinant spider silk proteins via transgenic silkworms, a core product category defined as Recombinant Proteins & Enzymes.
|
$86.47M |
$0.08
|
|
EUDA
EUDA Health Holdings Limited
EUDA's core biotech activity is a stem cell platform and cell therapy development using iPSCs.
|
$85.82M |
$2.27
+0.44%
|
|
INVE
Identiv, Inc.
Healthcare-focused applications (biometric sensing, device authentication) intersect with medical device/biometrics themes.
|
$84.92M |
$3.50
+2.49%
|
|
BMEA
Biomea Fusion, Inc.
Direct product category: Biomea Fusion is developing oral small molecule therapeutics, including icovamenib and BMF-650.
|
$84.50M |
$1.42
+5.97%
|
|
INO
Inovio Pharmaceuticals, Inc.
INO's core DNA medicines platform and lead candidate INO-3107 are gene therapy products based on DNA plasmids delivered via CELLECTRA; maps to gene therapy.
|
$84.50M |
$1.57
-0.94%
|
|
AMWL
American Well Corporation
Amwell uses Carepoint and related hardware as part of its care-delivery ecosystem, aligning with medical devices/biometrics.
|
$83.51M |
$5.21
+0.77%
|
|
LUNG
Pulmonx Corporation
Zephyr Endobronchial Valve and related medical devices are core product offerings.
|
$83.12M |
$2.00
-4.76%
|
|
TIL
Instil Bio, Inc.
Instil Bio's lead candidate AXN-2510/IMM2510 is a bispecific antibody, placing the company squarely in the Bispecific Antibodies investable theme.
|
$82.97M |
$5.79
-52.89%
|
|
CRDL
Cardiol Therapeutics Inc.
Cardiol Therapeutics' lead drug is a cardiovascular therapy targeting heart disease.
|
$82.45M |
$1.00
|
|
LFVN
LifeVantage Corporation
LoveBiome's microbiome/gut-health focus expands into digestive-health supplement opportunities.
|
$82.36M |
$6.53
+2.92%
|
|
BEAT
HeartBeam, Inc.
Direct diagnostic equipment derived from HeartBeam's synthesized 12-lead ECG device.
|
$82.35M |
$2.33
-1.06%
|
|
PLRX
Pliant Therapeutics, Inc.
Company's lead and mid-stage assets include oral small-molecule therapeutics (bexotegrast and PLN-101095) targeting integrin pathways.
|
$81.03M |
$1.32
+1.15%
|
|
OM
Outset Medical, Inc.
Outset's Tablo Hemodialysis System is a medical device; tag as Medical Devices & Biometrics.
|
$81.01M |
$4.53
-3.00%
|
|
ANVS
Annovis Bio, Inc.
The lead candidate Buntanetap is positioned as an Alzheimer's disease (AD) therapeutics program with cognition endpoints and an FDA-aligned path toward NDA filings.
|
$80.48M |
$4.17
+10.16%
|
|
ATOS
Atossa Therapeutics, Inc.
Atossa is a clinical-stage biotech focused on oncology with Z-endoxifen as its lead cancer therapy candidate.
|
$79.72M |
$0.66
+7.68%
|
|
ACRV
Acrivon Therapeutics, Inc. Common Stock
Companion Diagnostics: The company develops the OncoSignature companion diagnostic to identify patients likely to respond to its therapies.
|
$79.58M |
$2.56
+1.19%
|
|
HYPR
Hyperfine, Inc.
Hyperfine's Swoop portable MRI is a medical imaging device, directly fitting the Medical Imaging category.
|
$79.37M |
$1.00
+0.37%
|
|
VOR
Vor Biopharma Inc.
Vor Biopharma is focused on engineered cell therapies (eHSCs) and trem-cel, a cell therapy product.
|
$79.24M |
$12.50
+3.05%
|
|
MREO
Mereo BioPharma Group plc
Mereo's core focus is developing therapeutics for rare diseases, fitting the Biotech - Rare Diseases category.
|
$78.66M |
$0.48
+24.71%
|
|
NSPR
InspireMD, Inc.
InspireMD's core products are vascular/interventional endovascular devices (carotid stent systems with embolic protection).
|
$78.43M |
$1.82
-3.19%
|
Showing page 26 of 38 (3755 total stocks)
Loading company comparison...
Loading industry trends...
Loading research report...
